Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

(I) REVISED EXPECTED TIMETABLE IN RELATION TO PROPOSED CAPITAL REORGANISATION AND CONNECTED TRANSACTION FOR PROPOSED ALTERATION TO THE TERMS OF THE EXISTING CONVERTIBLE BONDS; AND (II) EXTENSION OF LONG STOP DATE OF THE SUBSCRIPTION AGREEMENT

UPDATE ON THE CAPITAL REORGANISATION AND REVISED EXPECTED TIMETABLE

Reference is made to the circular (the "**Circular 1**") of Wai Chun Bio-Technology Limited (the "**Company**") dated 28 March 2025, the announcements of the Company dated 23 April 2025, 21 May 2025, 21 August 2025, 11 September 2025 and 29 September 2025 (the "**Announcements**"). Unless otherwise defined or the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular 1 and the Announcements.

As disclosed in the Circular 1 and the Announcements, the effective date and time of the Capital Reorganisation was expected to be on 28 October 2025 and commencement of dealings in the New Ordinary Shares was expected to be at 9:00 a.m. on 28 October 2025, subject to, inter alia, the Registration by the Registrar of Companies in the Cayman Islands of a copy of the order of the Grand Court confirming the Capital Reduction and the minute approved by the Grand Court containing the particulars required under the Companies Act with respect to the Capital Reduction. As at the date of this announcement, the Company has been granted an order confirming the Capital Reduction by the Grand Court but additional time is required for the Registration. Accordingly set out below is the revised expected timetable in relation to the Capital Reorganisation and the connected transaction for Alteration of Terms:

Event(s)	**Time and Date**
Latest date and time for lodging transfer(s) of the Existing Ordinary Shares in order to qualify for attending and voting at the EGM	4:00 p.m. on Tuesday, 24 June 2025
Closure of register of members of the Company for determining the entitlement to attend and Vote at the EGM (both dates inclusive)	Wednesday, 25 June 2025 to Monday, 30 June 2025
Latest date and time for lodging forms of proxy for the EGM	3:00 p.m. on Saturday, 28 June 2025
Record date for attendance and voting at the EGM	Monday, 30 June 2025
Expected time and date of the EGM	3:00 p.m. on Monday, 30 June 2025
Publication of announcement of poll results of the EGM	Monday, 30 June 2025

The following events are conditional on the fulfilment of the conditions for the implementation of the Capital Reorganisation and therefore the dates are tentative only.

Expected effective date of the Capital Reorganisation	Friday, 14 November 2025
Dealing in the New Ordinary Shares commences	9:00 a.m. on Friday, 14 November 2025

All times and dates specified in the timetable above refer to Hong Kong times and dates.

The timetable is indicative only and may be extended or varied. Any change to the expected timetable above will be announced by the Company as and when appropriate.

EXTENSION OF LONG STOP DATE IN RELATION TO THE ALTERATION CONSENT LETTERS

Pursuant to the Alteration Consent Letters, the supplemental letters, the second supplemental letters, the third supplemental letters, the fourth supplemental letters, the fifth supplemental letters and the sixth supplemental letters, completion of the Alteration of Terms is conditional upon and subject to all the conditions precedent thereto being fulfilled or waived on or before the Long Stop Date, i.e. 31 October 2025. As additional time is required to procure the fulfillment of the conditions precedent, the Company and the Existing Bondholders entered into the seventh supplemental letters on 28 October 2025 (after trading hours) for further extension of the Long Stop Date to 30 November 2025 (or such later date as may be agreed by the Company and the Existing Bondholders) for each Alteration Consent Letters. Save as disclosed in this announcement, all other terms and conditions of the Alteration Consent Letters remain unchanged and in full force and effect.

EXTENSION OF LONG STOP DATE IN RELATION TO THE SUBSCRIPTION AGREEMENT

Reference is made to the circular (the "**Circular 2**") of the Company dated 25 August 2025 and the announcement of the Company dated 29 September 2025 (the "**Announcement**"). Unless otherwise defined or the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular 2 and the Announcement.

Pursuant to the terms and conditions of the Subscription Agreement, the First Supplemental Agreement, the Second Supplemental Agreement and the third supplemental agreement, completion of the Subscription Agreement is subject to the conditions precedent being fulfilled or waived (as the case may be) on or before 31 October 2025 (or such other date as may be agreed by the Company and the Existing Bondholder 1), being the Long Stop Date of the Subscription Agreement as amended by the First Supplemental Agreement, the Second Supplemental Agreement and the third supplemental agreement.

On 28 October 2025 (after trading hours), the Company and the Existing Bondholder 1 has entered into a fourth supplemental agreement, pursuant to which the parties agreed to extend the Long Stop Date of the Subscription Agreement to 30 November 2025 (or such other date as may be agreed by the Company and the Existing Bondholder 1) as additional time is required for the Company and the Existing Bondholder 1 to procure the fulfillment of the conditions precedent.

Save for the above, all other terms and conditions of the Subscription Agreement shall remain in full force and effect.

Completion of the Subscription, which is subject to the fulfilment of the conditions precedent set out in the Subscription Agreement, may or may not take place. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares and other securities of the Company.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Chief Executive Officer

Hong Kong, 28 October 2025

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer) and three independent non-executive Directors, namely Mr. Wang Ziniu, Ms. Xu Huiling and Mr. Wong Po Keung.